8 completed, 3 withdrawn, 2 terminated, 2 unknown. 8 Not applicable, 4 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 8 | Completed 4, Unknown 2, Recruiting 1, Terminated 1 |
| Phase 2 | 4 | Completed 2, Terminated 1, Withdrawn 1 |
| Phase 1 | 2 | Completed 1, Withdrawn 1 |
| Phase 3 | 1 | Withdrawn 1 |
Follow Ensure: new trials by email Literature Review of Ensure trials Research Report on Ensure
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Percent Weight Change in the Medical Supplement Group of Early Breast Cancer Ensure - Early Stage Breast Cancer | Not applicable | Unknown | Department of Medical Services Ministry of Public Health of Thailand | 40 | 2023-07-12 | 2024-12-27 |
| Prehabilitation for Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Behavioral Counseling, Nutritional Supplement Drink, Physical Activity - Advanced Ovarian Carcinoma, Stage IIIC Fallopian Tube Cancer AJCC v8 | Not applicable | Completed | Mayo Clinic | 90 | 2021-10-05 | 2025-08-08 |
| Oral Nutritional Optimization in Total Joint Arthroplasty Ensure - Osteoarthritis | Not applicable | Recruiting | NYU Langone Health | 72 | 2021-07-06 | 2025-09-11 |
| The Effects of Perioperative Nutritional Optimization on Blood Markers Ensure - Intervertebral Disc Disorders With Radiculopathy, Lumbar Region | Not applicable | Completed | NYU Langone Health | 120 | 2020-07-20 | 2022-06-22 |
| Effectiveness of Enteral Nutrition for Dose Reduction of Low Dose PEG Enteral Nutrition Powder Ensure, 1.5L PEG, Self-controlled diet - Bowel Preparation | Not applicable | Unknown | Ningbo No. 1 Hospital | 248 | 2019-08-01 | 2019-07-16 |
| Nutritional Supplementation in Reducing Complications in Patients With Locally Advanced Esophageal Cancer Undergoing Chemotherapy, Radiation Therapy, and/or Surgery Nutritional Supplement Drink, Nutritional Supplementation - Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8 | Phase 3 | Withdrawn | M.D. Anderson Cancer Center | 2019-03-14 | 2024-02-13 | |
| Evaluating Predictive Methods & Product Performance in Healthy Adults for Pediatric Patients, A Case Study: Furosemide Water, Parmalat™ Whole Milk, Similac Pro-Advance™ - Medication Absorption | Phase 1 | Withdrawn | Yale University | 2018-12-31 | 2019-01-18 | |
| Applying Nutrient Drink Test in Understanding Pathophysiology of CVS Ensure - Cyclic Vomiting Syndrome | Completed | The Cleveland Clinic | 24 | 2018-02-01 | 2020-02-27 | |
| Perioperative Immunonutrition for Patients Undergoing CRS and HIPEC IMPACT immunotherapy, ENSURE - Peritoneal Metastases | Not applicable | Completed | National Cancer Centre, Singapore | 70 | 2017-04-23 | 2019-09-20 |
| Oral Nutrition Supplementation in Hospitalized Patients Ensure - Malnutrition | Not applicable | Completed | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 63 | 2016-10-05 | 2019-03-14 |
| Ubiquinol as a Metabolic Resuscitator in Post-Cardiac Arrest Ubiquinol, Ensure - Cardiac Arrest | Phase 2 | Completed | Beth Israel Deaconess Medical Center | 48 | 2016-03-01 | 2021-02-15 |
| Routine Post-Operative Supplemental Nutrition Tube Feeding - Esophageal Cancer | Not applicable | Terminated | University of Michigan | 30 | 2014-11-01 | 2020-08-27 |
| Evaluation of the Effect of Fasting and Exercise on Uptake of Tc-99m Sestamibi in Breast Tissue Meal, Exercise, Sestamibi - Molecular Imaging | Phase 1 | Completed | Mayo Clinic | 154 | 2013-09-01 | 2017-04-18 |
| Improving Tolerance of Treatment of Pulmonary MAC Infections Zofran (8mg), Ensure - Mycobacterium Avium Complex, Adverse Effects | Phase 2 | Withdrawn | University of Florida | 2013-01-01 | 2013-04-04 | |
| Cyproheptadine Hydrochloride and Nutritional Supplementation in Treating Young Patients With Weight Loss With Cancer Ensure, PediaSure, cyproheptadine hydrochloride - Leukemia, Lymphoma | Phase 2 | Terminated | University of South Florida | 9 | 2009-09-01 | 2014-04-02 |
| Phase II Pharmacokinetics Study of Humalog and Humulin-R With and Without rHuPH20 in Type 1 Diabetes Mellitus Humalog, Humulin-R, Recombinant human hyaluronidase PH20 (rHuPH20) - Type 1 Diabetes Mellitus | Phase 2 | Completed | Halozyme Therapeutics | 22 | 2008-10-01 | 2019-02-26 |
Malnutrition (2) · Body Weight Changes (1) · Burkitt Lymphoma (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Diabetes Mellitus, Type 1 (1) · Esophageal Neoplasms (1) · Fallopian Tube Neoplasms (1) · Familial cyclic vomiting syndrome (1) · Fasting (1) · Heart Arrest (1) · Insulin Resistance (1) · Leukemia (1) · Lymphoma (1) · Lymphoma, Extranodal NK-T-Cell (1) · Lymphoma, Large B-Cell, Diffuse (1)
Mayo Clinic (2) · NYU Langone Health (2) · Beth Israel Deaconess Medical Center (1) · Department of Medical Services Ministry of Public Health of Thailand (1) · Halozyme Therapeutics (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) · M.D. Anderson Cancer Center (1) · National Cancer Centre, Singapore (1) · Ningbo No. 1 Hospital (1) · The Cleveland Clinic (1) · University of Florida (1) · University of Michigan (1) · University of South Florida (1) · Yale University (1)
United States (9) · Canada (1) · China (1) · Singapore (1) · Thailand (1)
Adam Rahman, MD, FRCPC (1) · Amanika A. Kumar, MD (1) · Hongpeng Lu, master (1) · Jeffrey Testani, MD (1) · Kevin P Fennelly, MD, MPH (1) · Linda A Morrow, M.D. (1) · Marisa Couluris, DO (1) · Melissa Teo, MD (1) · Michael K O'Connor, PhD, R-D (1) · Michael W Donnino, MD (1) · Peter Passias, MD (1) · Philip W Carrott, MD (1) · Piyawan Tienchaiananda (1) · Ran Schwarzkopf (1) · Scott Gabbard, MD (1)
PMID 21045179, PMID 21273493, PMID 24748626, PMID 25613340, PMID 29952503, PMID 30479286, PMID 33946039, PMID 40106001, PMID 7424938, PMID 8410128
R44CA143716 (1), U10CA081920 (1)